跳到正文
原文
Medical Xpress·· 2026-10-02AI 评分49

UTSW研究:仿制药与原研多发性硬化药物在血清生物标志物上存在差异

Generic, brand-name multiple sclerosis drugs may produce varied effects

AI 导读

UTSW研究人员分析1124例多发性硬化患者的血清生物标志物数据,发现服用富马酸二甲酯、芬戈莫德和特立氟胺仿制药版本的患者,其多种免疫相关蛋白的 biomarker 谱一致性低于服用原研药版本的患者,研究发表于 Clinical Immunology(DOI: 10.1016/j.clim.2026.110766)。

正文
Generic, brand-name MS drugs may produce varied effects
Protein–protein interaction network generated using STRING demonstrating molecular targets of monomethyl fumarate (an inhibitor of NF-κB pro-inflammatory expression). Credit: Clinical Immunology (2026). DOI: 10.1016/j.clim.2026.110766

A study led by UTSW researchers found that patients with multiple sclerosis (MS) taking generic versions of three commonly prescribed oral therapies had greater variability in blood proteins associated with MS disease activity than patients taking brand-name versions of the drugs.

Researchers analyzed serum biomarker data from 1,124 patients and found that generic formulations of dimethyl fumarate, fingolimod and teriflunomide were linked to less consistent biomarker profiles across multiple immune-related proteins. Published in Clinical Immunology, the findings suggest some generic MS therapies may produce more variable biological effects, potentially reflecting differences in drug exposure and less consistent disease control.

Although the study did not evaluate clinical outcomes such as relapse rates or disability progression, the results raise important questions about whether biological differences between generic and brand-name medications could affect treatment consistency. The findings underscore the need for further research to determine whether these biomarker differences translate into meaningful variations in patient outcomes and treatment effectiveness.

Publication details

Darin T. Okuda et al, Comparative multi-analyte serum protein differences between generic and brand-name dimethyl fumarate, fingolimod, and teriflunomide in multiple sclerosis, Clinical Immunology (2026). DOI: 10.1016/j.clim.2026.110766

Journal information: Clinical Immunology

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Generic, brand-name multiple sclerosis drugs may produce varied effects (2026, October 2) retrieved 2 October 2026 from https://medicalxpress.com/news/2026-10-generic-brand-multiple-sclerosis-drugs.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com